• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
RSV burden and prevention in children in LMICs.低收入和中等收入国家儿童呼吸道合胞病毒负担及预防
Lancet Glob Health. 2024 Oct;12(10):e1563-e1564. doi: 10.1016/S2214-109X(24)00289-4. Epub 2024 Aug 28.
2
Cost-effectiveness of pharmaceutical strategies to prevent respiratory syncytial virus disease in young children: a decision-support model for use in low-income and middle-income countries.预防小儿呼吸道合胞病毒病的药物策略的成本效益：用于低收入和中等收入国家的决策支持模型。
BMC Med. 2023 Apr 11;21(1):138. doi: 10.1186/s12916-023-02827-5.
3
New respiratory syncytial virus immunization products in low- and middle-income countries: potential for cost-effective impact on a high burden of disease in young infants.新型呼吸道合胞病毒疫苗在中低收入国家的应用：对婴幼儿高发疾病具有潜在的成本效益影响。
BMC Med. 2023 May 15;21(1):177. doi: 10.1186/s12916-023-02883-x.
4
Challenges in the prevention or treatment of RSV with emerging new agents in children from low- and middle-income countries.在中低收入国家，用新型制剂预防或治疗 RSV 面临的挑战。
Expert Rev Anti Infect Ther. 2021 Apr;19(4):419-441. doi: 10.1080/14787210.2021.1828866. Epub 2020 Dec 8.
5
Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and middle-income countries: a modelling study.呼吸道合胞病毒的季节性和低收入及中等收入国家婴儿被动免疫预防策略规划：建模研究。
Lancet Infect Dis. 2021 Sep;21(9):1303-1312. doi: 10.1016/S1473-3099(20)30703-9. Epub 2021 May 6.
6
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.2019 年全球、区域和国家因呼吸道合胞病毒导致 5 岁以下儿童急性下呼吸道感染的疾病负担估计：系统分析。
Lancet. 2022 May 28;399(10340):2047-2064. doi: 10.1016/S0140-6736(22)00478-0. Epub 2022 May 19.
7
New advances in RSV: Is prevention attainable?呼吸道合胞病毒的新进展：预防是否可行？
Pediatr Pulmonol. 2025 Mar;60 Suppl 1(Suppl 1):S120-S122. doi: 10.1002/ppul.27310. Epub 2024 Oct 28.
8
Severe respiratory syncytial virus infection in children: burden, management, and emerging therapies.儿童严重呼吸道合胞病毒感染：负担、管理和新兴疗法。
Lancet. 2024 Sep 21;404(10458):1143-1156. doi: 10.1016/S0140-6736(24)01716-1. Epub 2024 Sep 9.
9
Clinical and epidemiologic features of respiratory syncytial virus.呼吸道合胞病毒的临床和流行病学特征。
Curr Top Microbiol Immunol. 2013;372:39-57. doi: 10.1007/978-3-642-38919-1_2.
10
A community health concern: respiratory syncytial virus and children.社区健康关注点：呼吸道合胞病毒与儿童
J Pediatr Nurs. 2010 Dec;25(6):551-4. doi: 10.1016/j.pedn.2010.06.011. Epub 2010 Aug 19.

引用本文的文献

1
Interaction Between the Matrix Protein and the Polymerase Complex of Respiratory Syncytial Virus.呼吸道合胞病毒基质蛋白与聚合酶复合物之间的相互作用
Viruses. 2024 Dec 4;16(12):1881. doi: 10.3390/v16121881.

本文引用的文献

1
Respiratory syncytial virus infection among children younger than 2 years admitted to a paediatric intensive care unit with extended severe acute respiratory infection in ten Gavi-eligible countries: the RSV GOLD-ICU Network study.在十个符合全球疫苗免疫联盟资格的国家中，患有延长严重急性呼吸道感染的 2 岁以下儿童被送入儿科重症监护病房，其中发生的呼吸道合胞病毒感染：RSV GOLD-ICU 网络研究。
Lancet Glob Health. 2024 Oct;12(10):e1611-e1619. doi: 10.1016/S2214-109X(24)00269-9. Epub 2024 Aug 28.
2
Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study.尼赛珠单抗在西班牙加利西亚为婴儿进行普遍预防对呼吸道合胞病毒住院治疗的效果和影响：一项基于人群的纵向研究的初步结果。
Lancet Infect Dis. 2024 Aug;24(8):817-828. doi: 10.1016/S1473-3099(24)00215-9. Epub 2024 Apr 30.
3
Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024.2023 年 10 月至 2024 年 2 月，新疫苗监测网络对婴儿进入首个呼吸道合胞病毒季节时，尼赛珠单抗预防呼吸道合胞病毒相关住院的早期效果评估。
MMWR Morb Mortal Wkly Rep. 2024 Mar 7;73(9):209-214. doi: 10.15585/mmwr.mm7309a4.
4
Estimating the impact of COVID-19 vaccine inequities: a modeling study.估算 COVID-19 疫苗分配不均的影响：一项建模研究。
Nat Commun. 2023 Jun 6;14(1):3272. doi: 10.1038/s41467-023-39098-w.
5
Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants.孕期接种二价融合前F疫苗预防婴儿呼吸道合胞病毒疾病
N Engl J Med. 2023 Apr 20;388(16):1451-1464. doi: 10.1056/NEJMoa2216480. Epub 2023 Apr 5.
6
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.2019 年全球、区域和国家因呼吸道合胞病毒导致 5 岁以下儿童急性下呼吸道感染的疾病负担估计：系统分析。
Lancet. 2022 May 28;399(10340):2047-2064. doi: 10.1016/S0140-6736(22)00478-0. Epub 2022 May 19.
7
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.尼赛珠单抗预防健康晚期早产儿和足月婴儿 RSV 感染。
N Engl J Med. 2022 Mar 3;386(9):837-846. doi: 10.1056/NEJMoa2110275.
8
Deaths Attributed to Respiratory Syncytial Virus in Young Children in High-Mortality Rate Settings: Report from Child Health and Mortality Prevention Surveillance (CHAMPS).高死亡率环境下导致幼儿死亡的呼吸道合胞病毒：来自儿童健康和死亡率监测预防项目（CHAMPS）的报告。
Clin Infect Dis. 2021 Sep 2;73(Suppl_3):S218-S228. doi: 10.1093/cid/ciab509.
9
National burden estimates of hospitalisations for acute lower respiratory infections due to respiratory syncytial virus in young children in 2019 among 58 countries: a modelling study.2019 年 58 个国家因呼吸道合胞病毒导致的急性下呼吸道感染而住院的 5 岁以下儿童的国家负担估计：一项建模研究。
Lancet Respir Med. 2021 Feb;9(2):175-185. doi: 10.1016/S2213-2600(20)30322-2. Epub 2020 Sep 21.
10
Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study.无 HIV 感染的非洲和亚洲儿童需住院治疗的严重肺炎的病因：PERCH 多国家病例对照研究。
Lancet. 2019 Aug 31;394(10200):757-779. doi: 10.1016/S0140-6736(19)30721-4. Epub 2019 Jun 27.

RSV burden and prevention in children in LMICs.

作者信息

MacNeil Adam, McMorrow Meredith

机构信息

Coronaviruses and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.

Coronaviruses and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.

出版信息

Lancet Glob Health. 2024 Oct;12(10):e1563-e1564. doi: 10.1016/S2214-109X(24)00289-4. Epub 2024 Aug 28.

DOI:10.1016/S2214-109X(24)00289-4
PMID:39216501
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11874069/
Abstract
摘要